Pfizer Pursues FDA Approval for Lyme Disease Vaccine Despite Trial Results

Pfizer announced on Monday it will seek regulatory approval for its Lyme disease vaccine candidate, PF-07307405 (LB6V), despite the fact that a late-stage trial did not meet its pre-defined statistical goals. The decision comes as the pharmaceutical giant aims to introduce the first human vaccine for Lyme disease, a potentially significant advancement in preventing the debilitating illness.

Trial Results and Efficacy

The Phase 3 VALOR trial, conducted in the U.S., Canada, and Europe, demonstrated an efficacy of over 70% in preventing Lyme disease in individuals aged five years, and above. Specifically, the vaccine showed 74.8% efficacy from one day after the fourth dose and 73.2% efficacy 28 days post-dose 4. Pfizer and its partner, Valneva, reported these findings on March 23, 2026.

However, the trial fell short of its primary endpoint – a pre-determined 95% confidence interval – due to a lower-than-expected number of Lyme disease cases accrued during the study period. CNBC reported that Pfizer attributed this to insufficient infections among study participants, making it difficult to establish statistical significance.

Confidence in the Vaccine’s Potential

Despite the statistical setback, Pfizer expressed confidence in the vaccine’s potential. “Given the clinically meaningful efficacy and the fact that the 95% confidence interval lower bound was above 20 in the second pre-specified analysis, Pfizer is confident in the vaccine’s potential and is planning submissions to regulatory authorities,” Pfizer stated in a press release. BioSpace highlighted this sentiment, noting that the company believes the over 70% efficacy is strong enough to warrant regulatory review.

Market Potential and Future Outlook

Valneva estimates that the Lyme disease vaccine could reach peak annual sales exceeding $1 billion. Pfizer anticipates overall revenue of approximately $60 billion this year, with its COVID-19 vaccine contributing over $5 billion. While the Lyme vaccine isn’t expected to be a blockbuster, it represents a significant opportunity to address an unmet medical need.

The decision to move forward with a vaccine that technically failed a clinical trial could be a test of vaccine policy in the U.S., particularly under increased scrutiny from regulators. CNBC noted that this move may be considered risky, but Pfizer remains optimistic about its prospects.

Key Takeaways

• Pfizer will seek FDA approval for its Lyme disease vaccine despite a late-stage trial failing to meet its primary statistical goal.
• The vaccine demonstrated over 70% efficacy in preventing Lyme disease.
• The trial’s primary endpoint was not met due to a lower-than-expected number of Lyme disease cases during the study.
• Valneva estimates peak annual sales of the vaccine could exceed $1 billion.